Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination

Viruses expressing tumour antigens can prime and boost anti-tumour immunity but the efficiency of this approach depends on the capacity of the virus to infect the host. Here, the authors show that vaccination with oncolytic viruses co-administered with tumour antigenic peptides is as efficient as an...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	D. G. Roy, K. Geoffroy, M. Marguerie, S. T. Khan, N. T. Martin, J. Kmiecik, D. Bobbala, A. S. Aitken, C. T. de Souza, K. B. Stephenson, B. D. Lichty, R. C. Auer, D. F. Stojdl, J. C. Bell, M.-C. Bourgeois-Daigneault
Format:	article
Langue:	EN
Publié:	Nature Portfolio 2021
Sujets:	Science Q
Accès en ligne:	https://doaj.org/article/0087d0d0e932497c868d4c3d99452a6d
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

id	oai:doaj.org-article:0087d0d0e932497c868d4c3d99452a6d
record_format	dspace
spelling	oai:doaj.org-article:0087d0d0e932497c868d4c3d99452a6d2021-12-02T14:35:46ZAdjuvant oncolytic virotherapy for personalized anti-cancer vaccination10.1038/s41467-021-22929-z2041-1723https://doaj.org/article/0087d0d0e932497c868d4c3d99452a6d2021-05-01T00:00:00Zhttps://doi.org/10.1038/s41467-021-22929-zhttps://doaj.org/toc/2041-1723Viruses expressing tumour antigens can prime and boost anti-tumour immunity but the efficiency of this approach depends on the capacity of the virus to infect the host. Here, the authors show that vaccination with oncolytic viruses co-administered with tumour antigenic peptides is as efficient as antigen-engineered oncolytic viruses.D. G. RoyK. GeoffroyM. MarguerieS. T. KhanN. T. MartinJ. KmiecikD. BobbalaA. S. AitkenC. T. de SouzaK. B. StephensonB. D. LichtyR. C. AuerD. F. StojdlJ. C. BellM.-C. Bourgeois-DaigneaultNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q D. G. Roy K. Geoffroy M. Marguerie S. T. Khan N. T. Martin J. Kmiecik D. Bobbala A. S. Aitken C. T. de Souza K. B. Stephenson B. D. Lichty R. C. Auer D. F. Stojdl J. C. Bell M.-C. Bourgeois-Daigneault Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination
description	Viruses expressing tumour antigens can prime and boost anti-tumour immunity but the efficiency of this approach depends on the capacity of the virus to infect the host. Here, the authors show that vaccination with oncolytic viruses co-administered with tumour antigenic peptides is as efficient as antigen-engineered oncolytic viruses.
format	article
author	D. G. Roy K. Geoffroy M. Marguerie S. T. Khan N. T. Martin J. Kmiecik D. Bobbala A. S. Aitken C. T. de Souza K. B. Stephenson B. D. Lichty R. C. Auer D. F. Stojdl J. C. Bell M.-C. Bourgeois-Daigneault
author_facet	D. G. Roy K. Geoffroy M. Marguerie S. T. Khan N. T. Martin J. Kmiecik D. Bobbala A. S. Aitken C. T. de Souza K. B. Stephenson B. D. Lichty R. C. Auer D. F. Stojdl J. C. Bell M.-C. Bourgeois-Daigneault
author_sort	D. G. Roy
title	Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination
title_short	Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination
title_full	Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination
title_fullStr	Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination
title_full_unstemmed	Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination
title_sort	adjuvant oncolytic virotherapy for personalized anti-cancer vaccination
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/0087d0d0e932497c868d4c3d99452a6d
work_keys_str_mv	AT dgroy adjuvantoncolyticvirotherapyforpersonalizedanticancervaccination AT kgeoffroy adjuvantoncolyticvirotherapyforpersonalizedanticancervaccination AT mmarguerie adjuvantoncolyticvirotherapyforpersonalizedanticancervaccination AT stkhan adjuvantoncolyticvirotherapyforpersonalizedanticancervaccination AT ntmartin adjuvantoncolyticvirotherapyforpersonalizedanticancervaccination AT jkmiecik adjuvantoncolyticvirotherapyforpersonalizedanticancervaccination AT dbobbala adjuvantoncolyticvirotherapyforpersonalizedanticancervaccination AT asaitken adjuvantoncolyticvirotherapyforpersonalizedanticancervaccination AT ctdesouza adjuvantoncolyticvirotherapyforpersonalizedanticancervaccination AT kbstephenson adjuvantoncolyticvirotherapyforpersonalizedanticancervaccination AT bdlichty adjuvantoncolyticvirotherapyforpersonalizedanticancervaccination AT rcauer adjuvantoncolyticvirotherapyforpersonalizedanticancervaccination AT dfstojdl adjuvantoncolyticvirotherapyforpersonalizedanticancervaccination AT jcbell adjuvantoncolyticvirotherapyforpersonalizedanticancervaccination AT mcbourgeoisdaigneault adjuvantoncolyticvirotherapyforpersonalizedanticancervaccination
_version_	1718391050086645760

Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination

Documents similaires